This bill requires each local board of education to establish a policy for public schools to authorize the school nurse and other school personnel to administer a bronchodilator, if available, to a student who is determined by an individual with specified training, if available, to have asthma, is experiencing asthma-related symptoms, or is perceived to be in respiratory distress, regardless of whether the student has been (1) diagnosed with asthma or reactive airway disease or (2) prescribed a bronchodilator by a licensed health care practitioner. However, a bronchodilator may not be administered to a prekindergarten student without a prescription, as specified. The policy must include other specified elements. Likewise, the bill authorizes each nonpublic school to establish a policy that meets similar requirements. The bill also makes parallel changes to existing requirements for each local board of education’s epinephrine use policy. The bill takes effect July 1, 2022.

Fiscal Summary

State Effect: The Maryland State Department of Education (MSDE) and the Maryland Department of Health (MDH) can jointly identify and develop required trainings, develop required forms, and receive required incident reports using existing budgeted resources. Revenues are not affected.

Local Effect: Local school system expenditures increase minimally to develop policies and implement required training. Assuming school nurses decide to make bronchodilators and modes of administration available, annual school system and/or local health department (LHD) expenditures increase. To the extent a school system applies for and receives grants as authorized under the bill, revenues increase.
Small Business Effect: None. To the extent that nonpublic schools are small businesses, the bill authorizes, but does not require, the specified policy and related training and procedures.

Analysis

Bill Summary:

Anaphylaxis Identification Training

MSDE, in consultation with MDH, the American Lung Association, and the Asthma and Allergy Foundation of America, must identify or develop a training to identify the symptoms of asthma and respiratory distress, identify the symptoms of anaphylaxis, and distinguish between anaphylaxis and asthma or respiratory distress. The training must be provided to school nurses and voluntary school personnel who are designated by a school nurse and, in the clinical judgment of the school nurse, are appropriate recipients of the training. This training must be a paid professional development training.

Bronchodilator Policy and Availability

“School personnel” means individuals employed by a school (public or nonpublic, as relevant), including part-time employees, teachers and substitute teachers employed by the school at least seven days of each school year, registered nurse case managers, delegating nurses, and administrative staff.

The policy must include (1) a paid professional development training for school nurses and other voluntary school personnel designated by a school nurse on the identification and differentiation of anaphylaxis and asthma and respiratory distress; (2) procedures for the emergency administration of a bronchodilator by a school nurse or designated volunteer; (3) proper follow-up emergency procedures; (4) a provision authorizing a school nurse to obtain and store at a public school bronchodilators and modes of administration to be used in an emergency situation; and (5) a requirement that each public school develop and implement a method for notifying the parents or guardians of students of the school’s policy at the beginning of each school year. These elements are also required, as appropriate, for any policy voluntarily developed by nonpublic schools; however, nonpublic schools must also establish an ongoing process for oversight and monitoring by a licensed health care practitioner.

An authorized licensed health care practitioner may provide bronchodilators to a school nurse or designated volunteer for use in accordance with the bill. Bronchodilators
and modes of administration used by a school nurse or any other school personnel must be from a licensed pharmacy or manufacturer. A local board of education or public school (as well as a nonpublic school) may accept donated bronchodilators and modes of administration from a licensed pharmacy or manufacturer, and a local board (as well as a nonpublic school) may apply for grants to obtain funding for the purchase of bronchodilators and modes of administration.

MSDE must develop and disseminate standard forms to record and report each incident requiring the use of a bronchodilator at a public school. A public school must notify the student’s parent or legal guardian of an incident requiring the use of a bronchodilator and make a record of the incident on this form and file the form in the student’s school medical record. Each public school must submit a report to MSDE on the number of incidents at the school or at a related school event that required the use of a bronchodilator.

Except for any willful or grossly negligent act, a school nurse or any other school personnel who respond in good faith to the asthma attack or respiratory distress in accordance with the bill may not be held personally liable for any act or omission in the course of responding to the child in distress.

**Epinephrine Policy and Availability**

The training identified or developed by MSDE on the identification and differentiation of anaphylaxis and asthma and respiratory distress must be part of each local board of education’s epinephrine use policy as well as each nonpublic school’s policy (if the nonpublic school has opted to establish such a policy). Each epinephrine policy must also include procedures for the emergency administration of auto-injectable epinephrine by a school nurse or designated volunteer if the student is determined by an individual who has undergone training, if available, to be perceived to be in anaphylaxis.

An authorized licensed health care practitioner may provide auto-injectable epinephrine to a school nurse or designated volunteer for use as specified. Auto-injectable epinephrine must be from a licensed pharmacy or manufacturer. A local board of education or public school (as well as a nonpublic school) may accept donated auto-injectable epinephrine from a licensed pharmacy or manufacturer, and a local board (as well as a nonpublic school) may apply for grants to obtain funding for the purchase of epinephrine from a licensed pharmacy or manufacturer.

**Current Law:** With the assistance of the LHD, each local board of education must provide adequate school health services, instruction in health education, and a healthful school environment. MSDE and MDH must jointly develop public standards and guidelines for school health programs and offer assistance to the local boards of education and LHDs in their implementation.
MSDE and MDH must jointly establish guidelines for public schools regarding emergency care for students with special health needs. The guidelines must include procedures for the emergency administration of medication and the proper follow-up emergency procedures, a description of parental or caregiver responsibilities, a description of school responsibilities, a description of student responsibilities that are age and condition appropriate, and any other issue that is relevant to the emergency medical care of students with special health needs. MSDE and MDH must provide technical assistance to schools to implement the guidelines established, train designated school personnel at the local level, and develop a process to monitor the implementation of the guidelines.

Auto-injectable Epinephrine

“Anaphylaxis” means a sudden, severe, and potentially life-threatening allergic reaction that occurs when an individual is exposed to an allergen. “Auto-injectable epinephrine” means a portable, disposable drug delivery device that contains a premeasured single dose of epinephrine that is used to treat anaphylaxis in an emergency situation.

Each local board of education must establish a policy to authorize the school nurse and other school personnel to administer auto-injectable epinephrine, if available, to a student who is determined to be or perceived to be in anaphylaxis, regardless of whether the student (1) has been identified as having an anaphylactic allergy or (2) has a prescription for epinephrine from a licensed health care practitioner. The policy must also include training for school personnel on how to recognize the symptoms of anaphylaxis; procedures for the emergency administration of auto-injectable epinephrine; proper follow-up emergency procedures; and a provision authorizing a school nurse to obtain and store at a public school auto-injectable epinephrine to be used in an emergency situation. These elements are also required, as appropriate, for any policy voluntarily developed by nonpublic schools; however, nonpublic schools must also establish an ongoing process for oversight and monitoring by a licensed health care practitioner.

Each public school must submit, on the form that MSDE requires, a report on each incident at the school or at a related school event that required the use of auto-injectable epinephrine. MSDE must develop and disseminate a standard form to report each incident requiring the use of auto-injectable epinephrine at a public school.

Local Expenditures: LHDs provide school nurses in approximately 14 jurisdictions. Thus, LHD expenditures in those jurisdictions increase by a minimal amount for school nurses to attend specified paid professional development trainings. Local school system expenditures likewise increase for school nurses employed by local school systems and school staff designated by the school nurse to attend the specified paid professional development trainings. Costs will be less to the extent paid professional development
training is already provided and can be replaced by the specified training identified/developed by MSDE.

Assuming school nurses decide to make bronchodilators and spacers available, annual local school system and/or LHD expenditures increase. Should they do so, it is unknown what price local school systems will pay for stock bronchodilators and modes of administration, including spacers. According to Cost Helper, the cost to the general public for an albuterol rescue inhaler, which is one type of bronchodilator, is $30 to $60. Other bronchodilators and administration systems, such as nebulizers, may cost more or less than that estimate. Nurses in local schools will need to decide what bronchodilators and administration systems are most appropriate to stock. Baltimore City Public Schools estimates a cost of $40,000 annually to ensure there are two bronchodilators per school; Baltimore County Public Schools also estimates a cost of $40,000 annually to ensure there are three to five bronchodilators per school. Montgomery County Public Schools estimates a cost of $35,000 for medications and supplies.

Total costs are higher if school nurses determine that a greater stock supply of bronchodilators is necessary (which expire and must be replaced regularly). There may also be costs associated with the safe disposal of used and expired bronchodilators. To the extent local school systems currently have stock bronchodilators, licensed pharmacies or manufacturers donate supplies of bronchodilators, or local school systems secure grants for the purchase of bronchodilators and modes of administration, costs are mitigated.

Current law already requires that each local board’s auto-injectable epinephrine policy include a provision authorizing a school nurse or licensed health care practitioner to obtain auto-injectable epinephrine to be used in an emergency situation. Therefore, to the extent licensed pharmacies or manufacturers donate supplies of auto-injectable epinephrine or local school systems secure grants for the purchase of auto-injectable epinephrine as a result of the bill, local expenditures for auto-injectable epinephrine are also mitigated.

Additional Information

Prior Introductions: HB 609 of 2021, a related bill, received a hearing in the House Ways and Means Committee, but no further action was taken. HB 773 of 2020, another related bill, received a hearing in the House Ways and Means Committee, but no further action was taken.

Designated Cross File: None.